Hyderabad ORS controversy: Legal notices to paediatrician trigger nationwide medical solidarity
A legal dispute has erupted between Hyderabad paediatrician Dr Sivaranjani Santosh and pharmaceutical companies over allegations of high sugar content in products marketed as ORS. Medical associations have backed the doctor, calling the legal notices an attempt to silence public health advocacy.
Hyderabad: A growing confrontation between Hyderabad-based senior paediatrician and public health activist Dr Sivaranjani Santosh and major pharmaceutical companies has intensified, following legal notices served to her over allegations related to high sugar content in products marketed as Oral Rehydration Salts (ORS).
The legal action stems from her decade-long campaign questioning the marketing of high-sugar beverages under the ORS label. However, the move appears to have triggered widespread backlash, with medical associations and healthcare professionals across India condemning the notices as an attempt to intimidate a doctor advocating for public health.
Responding strongly, Dr Sivaranjani rejected the allegations, stating that her position is supported by regulatory directives issued by the Food Safety and Standards Authority of India in October. She also accused companies of misleading consumers through rebranding strategies, particularly shifting from ORSL to ERZL, which she said continues to confuse parents relying on these products for treating dehydration.
Medical bodies in Telangana, including the Telangana Senior Resident Doctors Association (T-SRDA) and the Healthcare Reforms Doctors Association (HRDA), have criticised the pharmaceutical companies, describing the notices as “legal intimidation” that undermines scientific integrity and restricts doctors from raising legitimate public health concerns. They have demanded an immediate withdrawal of the notices.
Origins of the Dispute
Dr Sivaranjani’s advocacy began over eight years ago, focusing on what she described as a critical public health issue: the misrepresentation of sugary beverages as ORS. She emphasised that ORS is a precisely formulated medical solution containing a specific balance of salts and glucose (dextrose) designed for rapid absorption and effective treatment of dehydration.
According to her, several manufacturers were selling drinks with high sugar content under the ORS label, potentially misleading consumers and compromising treatment outcomes.
As part of her efforts, she approached regulatory authorities, including the Central Drugs Standard Control Organisation, the Union Ministry of Health and Family Welfare, and the Food Safety and Standards Authority of India. She also raised the issue with Union Health Minister J P Nadda.
Regulatory Turning Point
A significant development came last year when the Food Safety and Standards Authority of India issued directives banning beverage products from using the term “Oral Rehydration Salts (ORS).” The decision marked a major regulatory shift in response to concerns about misleading labelling.
The move followed sustained advocacy and coincided with heightened scrutiny of pharmaceutical safety after the reported deaths of 25 children in Madhya Pradesh linked to contaminated syrup.
Describing the directive as a major public health victory, Dr Sivaranjani said the ORS label must remain exclusive to formulations that comply with World Health Organisation standards. She maintained that regulatory clarity would help prevent misuse and protect children from inappropriate treatment.
Clinical Concerns and Public Health Risks
Dr Sivaranjani has consistently argued that high-sugar products marketed as ORS can worsen diarrhoeal conditions in children. Based on her clinical experience, she noted that several paediatric cases involved children whose condition deteriorated after consuming such products.
She stressed that ORS is a medically approved formulation requiring clearance from the Central Drugs Standard Control Organisation, and that deviations from its prescribed composition can compromise its effectiveness.
“Replacing a life-saving solution with a sweetened beverage during diarrhoeal illness can be harmful,” she has maintained in her public statements.
Earlier regulatory measures had allowed companies to continue using the ORS label with disclaimers. However, Dr Sivaranjani opposed this compromise, arguing that disclaimers were insufficient to prevent consumer confusion. Her campaign gained significant traction after a social media video on the issue went viral, garnering over 3.3 million views.
International Regulatory Practices
Globally, countries such as the United States, the United Kingdom, and Australia maintain strict regulatory distinctions between ORS and commercial beverages. ORS is classified as a medical-grade rehydration therapy and must adhere to electrolyte and glucose ratios defined by the World Health Organisation.
In these markets, high-sugar beverages are categorised separately as recreational or sports drinks, with stringent labelling laws preventing misuse of terms like “rehydration” or “ORS” for non-compliant products. This clear demarcation ensures that consumers, particularly parents, can differentiate between therapeutic solutions and sugary drinks.
Current Situation
The ongoing dispute has now evolved into a broader debate on regulatory enforcement, corporate accountability, and the role of medical professionals in public health advocacy. While pharmaceutical companies have initiated legal action, the response from the medical community suggests growing support for stricter oversight of product labelling and marketing practices.
The outcome of this confrontation is likely to have significant implications for public health policy, regulatory clarity, and consumer protection in India’s healthcare and pharmaceutical sectors.
